Sage Therapeutics Inc. (SAGE)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
SAGE Chart
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates
Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to a loss of $1.7 per share a year ago.
What Makes Sage Therapeutics (SAGE) a New Buy Stock
Sage Therapeutics (SAGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal
SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.
Sage Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JM John Malone Amundi | 200,261 | $11,377.01 | $11,377.01 | - | - |
Sage Therapeutics Inc. (SAGE) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Sage Therapeutics Inc. Profile
| - Industry | - Sector | Barry E. Greene CEO | NASDAQ (NMS) Exchange | 78667J108 CUSIP |
| US Country | 353 Employees | - Last Dividend | - Last Split | 18 Jul 2014 IPO Date |
Overview
Sage Therapeutics, Inc. stands out as a pioneering biopharmaceutical entity dedicated to the advancement and commercialization of innovative brain health medications. Originating from its initial establishment as Sterogen Biopharma, Inc., the company embarked on a new chapter by adopting its current name in September 2011. With its roots planted in 2010, Sage Therapeutics, Inc. is strategically positioned in Cambridge, Massachusetts, serving as a beacon of hope and innovation in the realm of neuroscience. The company's vision extends beyond the conventional, targeting a broad spectrum of neurological and psychiatric conditions through a vibrant pipeline of therapeutic candidates and established collaborations, notably with Shionogi & Co., Ltd. and Biogen MA Inc. These partnerships are instrumental in harnessing global resources for the development and dissemination of groundbreaking treatments tailored to address unmet medical needs in brain health.
Products and Services
- ZULRESSO
A pivotal development by Sage Therapeutics, Inc., ZULRESSO is heralded as a breakthrough treatment for postpartum depression (PPD) in adults. It distinguishes itself as a CIV injection, demonstrating the company's commitment to offering novel therapeutic options for mental health conditions.
- ZURZUVAE
ZURZUVAE emerges as a neuroactive steroid and a potent positive allosteric modulator of GABAA receptors. It intricately targets both synaptic and extrasynaptic GABAA receptors, presenting a promising therapeutic avenue for individuals grappling with postpartum depression. This approach reflects Sage's dedication to exploring and understanding the complex neural pathways associated with mood disorders.
- SAGE-324
Stepping into the realm of neurological disorders, SAGE-324 is currently undergoing Phase II clinical trials aimed at treating essential tremors. Additionally, its scope has been extended to explore therapeutic potentials in epilepsy and Parkinson's disease, having completed Phase I clinical trials. SAGE-324 represents Sage Therapeutics' broader mission to confront a variety of central nervous system disorders with cutting-edge science.
- SAGE-718
Another cornerstone of Sage's innovative pipeline, SAGE-718 leverages the properties of oxysterol-based positive allosteric modulation of the NMDA receptor. Currently in Phase II clinical trials, this compound is being investigated for its potential to address a spectrum of conditions including depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. SAGE-718 embodies the company's strategic approach to targeting fundamental neuropathological mechanisms across a myriad of brain health challenges.
